BAY-41-8543 (CAS 256498-66-5)
QUICK LINKS
Soluble guanylate cyclase (sGC) is the primary cellular receptor for nitric oxide (NO). NO binds and activates a heme group in sGC, initiating the conversion of GTP to the second messenger cyclic GMP (cGMP). BAY-41-8543 is a heme-dependent stimulator of sGC, increasing the activity of recombinant sGC dose-dependently up to 92-fold. Surprisingly, NO donors synergize with BAY-41-8543 in stimulating recombinant sGC. BAY-41-8543 relaxes vessels and inhibits platelet aggregation in vitro at nM concentrations. In vivo, BAY-41-8543 decreases blood pressure dose-dependently, prolongs bleeding time, and reduces thrombosis. Inhalation of microparticles containing BAY-41-8543 increases pulmonary vasodilation without changing mean arterial pressure suggesting that agonists of sGC may be efficacious in treating pulmonary hypertension.
BAY-41-8543 (CAS 256498-66-5) References
1 Stasch, J., Alonso-Alija, C., Apeler, H., et al. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 135 333-343 (2002). 2 Stasch, J., Dembowsky, K., Perzborn, E., et al. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol 135 344-355 (2002). 3 Evgenov, O.V., Kohane, D.S., Bloch, K.D., et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med 176 1138-1145 (2007).Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BAY-41-8543, 1 mg | sc-291927 | 1 mg | $77.00 | |||
BAY-41-8543, 5 mg | sc-291927A | 5 mg | $605.00 |